Hogan Lovells

With several offices throughout the US and around the globe, Hogan Lovells maintains a strong international presence in the life sciences industry. The firm advises clients in the sector on all matters related to financing, licensing, and transactions. A peer praises the firm for its "excellent, deep knowledge of the life sciences industry."

Based in Baltimore, Asher Rubin is global head of the firm's life sciences group and is highly regarded for advising a variety of life sciences clients in a host of corporate and finance-related matters. In the past year, Rubin led the Hogan team representing NextCure, a biotechnology company focused on cancer and immune-related diseases, with its $86 million IPO as well as a development collaboration with Eli Lilly.

Adam Golden is head of the corporate group in New York, and represents clients in several high-profile transactions as well as collaboration agreements. Golden, who one peer describes as “very strong in the space,” recently advised Novartis in its strategic collaboration agreements with IFM Therapeutics.  

Philadelphia-based Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. Among his recent matters, Abrams represented Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) specialists, with its public offering worth $39 million.

Hogan Lovells is an international firm with a full-service practice in the life sciences area. The firm is notable for its all-encompassing regulatory practice, for which it receives top rankings across the board. The life sciences group also receives high ratings for its practices in M&A, licensing and collaboration and white-collar matters.

The firm's top-ranked regulatory practice includes "terrific" partner David Fox, who is highly regarded as an advisor to pharmaceutical companies in FDA clearance. He is currently representing AllerQuest in its FDA approval process for developing an innovative penicillin allergy test. Medical device advisor Jonathan Kahan boasts more than 40 years of experience practicing law. He is currently assisting Hitachi with FDA market clearance for its proton beam therapy (PBT) systems. In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field. She currently serves as chair of the firm's global regulatory practice. Another standout is Beth Roberts, who has a "stellar reputation" in reimbursement matters for life sciences companies.

A peer praises the firm for its "strong regulatory group supporting the transactional practices," and "excellent, deep knowledge of the life sciences industry" as it relates to corporate matters. Asher Rubin is global head of the firm's life sciences group, who recently advised Tesaro in its $5.1 billion acquisition by GlaxoSmithKline. Rubin was shortlisted by LMG Life Sciences for the Corporate Attorney of the Year award in 2019. Adam Golden is head of the life sciences corporate group and is well known for his representation of clients in high-profile transactions and collaboration agreements. He recently represented Celgene in its strategic collaboration with Obsidian Therapeutics. Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. He recently assisted in initial public offerings for Arbutus Biopharma and EyePoint Pharmaceuticals.

Jonathan Diesenhaus has extensive experience advising a number of life science clients involving criminal investigations and enforcement matters. Among his current clients, Diesenhaus represents William Beaumont Hospital in a multi-year investigation and associated qui tam litigation brought by the Department of Justice. Leading appellate practitioner Neal Katyal recently acted for Bristol-Myers Squibb and Pfizer in a multidistrict litigation that challenged the labeling of the clients' anticoagulant drug Eliquis, resulting in a successful dismissal with the verdict upheld on appeal. Lauren Colton recently represented Amgen as lead counsel in a number of product liability suits related to the client's biologic product Enbrel. Colton serves as head of the firm's products law practice group.

For IP matters, Arlene Chow is one of the firm's leading life sciences practitioners, with a deep focus on the biotechnology and pharmaceutical areas. She specializes in contentious proceedings before the Patent Office, an area of continued focus in her practice. According to a client, Chow has "a very deep knowledge of the law and the science and the industry. [Her] skills in depositions and at oral hearings are superb." Chow is currently handling IPR proceedings for Merck related to patents covering pneumococcal vaccine Prevnar 13.

DC-based Hogan Lovells is a global, full-service law firm that is widely considered a juggernaut in the life sciences industry, with its team of experts versed in antitrust litigation, white-collar defense and regulatory enforcement.

Jonathan Diesenhaus has extensive experience advising life science clients in criminal investigations and enforcement matters. Among his current representations, Diesenhaus is counsel for William Beaumont Hospital in a multi-year investigation and associated qui tam litigation by the Department of Justice. The claims involve alleged violations of the False Claims Act, Stark Law, and Anti-Kickback Statute.

Recently involved in the product liability space is Neal Katyal, who has earned his status as a leading appellate litigator with a strong track record in life sciences disputes. He recently represented Bristol-Myers Squibb (BMS) and Pfizer in a multi-district litigation that challenged the labeling of the clients' anticoagulant drug Eliquis. The case resulted in a successful dismissal with the verdict upheld on appeal. Prior to his private practice at Hogan Lovells, Katyal served as Solicitor General of the United States.

Co-headquartered in London and Washington DC, Hogan Lovells is consistently ranked for having one of the premier life sciences regulatory practices and is this year’s LMG Life Sciences Regulatory Firm of the Year. One client describes the firm as being "top-notch," with a group of attorneys who possess "a very deep knowledge of the law." The firm's depth gives it the ability to assist a variety of life sciences clients in all aspects of the regulatory process.

David Fox is highly regarded for assisting a number of pharmaceutical companies with their regulatory issues. One peer comments that Fox is "terrific," while another describes him as an "absolute star" in the field. Among his recent matters, Fox served as lead partner representing Intra-Cellular Therapies through the FDA approval process for the company’s Caplyta program, a treatment for schizophrenia.

Operating from both the firm's Washington, DC and Denver offices, Meredith Manning has over 20 years of experience counseling a variety of pharmaceutical clients in regulatory matters. One clients exclaims that Manning and her team "are extremely competent and knowledgeable on FDA regulatory matters" and are "responsive, thorough and able to explain complex rules in an understandable way."

Jonathan Kahan is a "star" according to one peer, and has over 40 years of experience assisting medical device and diagnostics companies with their regulatory issues. He was recently active for Vayu Global Health Innovations in relation to an Emergency Use Authorization for its bubble CPAP device.

In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field with one peer noting she has “great respect” for her work. She regularly advises clients on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Valder Curran currently serves as chair of the firm's global regulatory practice.

Beth Roberts is this year’s LMG Life Sciences Healthcare Pricing & Reimbursement Attorney of the year and is noted for representing a number of high-profile life sciences clients. One peer notes Roberts is “fantastic” to work with while another peer highlights she “top notch” in the field. Roberts served as lead regulatory counsel for Celgene in a noteworthy NCA matter related to CAR-T therapy.